Bavarian eyes Mpox vaccine label expansion to include toddlers, kickstarts Phase II trial
The registrational trial is expected to support the Bavarian’s mpox/smallpox vaccine use in children between 2 and 11 years of age.
30 October 2024
The registrational trial is expected to support the Bavarian’s mpox/smallpox vaccine use in children between 2 and 11 years of age.
The approval is based on the outcomes of the Phase III ASC4FIRST trial.
Dermavant is eligible to receive up to $1.2bn from Organon.
The SIRT6 activator’s sex-specific effects shed light on the different genetic profiles of depression between men and women.
Chimagen will receive up to $550m in success-based development and commercial milestone payments.
At the core of asthma disparities lies the geography of environmental racism, various studies have found.
At the Outsourcing in Clinical Trials Conference, government personnel advised attendees on the transport of biologics across borders.
Astellas chose to withdraw its application after discussions with the EMA’s Committee for Medicinal Products for Human Use.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.